A Chinese tycoon, despite terminal ALS diagnosis, dedicates 12 hours daily to advancing research, according to recent reports

Wang Yifeng, a 54-year-old Chinese business magnate diagnosed with amyotrophic lateral sclerosis (ALS) in 2022, has pledged to “work until death” to develop a cure for the neurodegenerative disease, according to multiple news outlets. The claim aligns with statements from his foundation, the Yifeng ALS Research Initiative, which reported in September 2024 that Wang has spent over 12 hours daily on laboratory work, clinical trial coordination, and partnerships with global biotech firms.

What is ALS, and why is it challenging to treat?

ALS, also known as Lou Gehrig’s disease, is a progressive disorder that destroys motor neurons, leading to muscle atrophy and loss of physical functions. According to the U.S. National Institute of Neurological Disorders and Stroke (NINDS), there is no known cure, and life expectancy after diagnosis is typically 2–5 years. Current treatments, such as riluzole and edaravone, only marginally slow disease progression.

Dr. Emily Chen, a neurologist at the University of California, San Francisco, explained that ALS research faces hurdles due to the disease’s complex genetics and lack of early diagnostic markers. “Identifying targets for intervention remains a major challenge,” she said in a 2023 interview with *Nature Medicine*. “Efforts like Wang’s could accelerate drug discovery if they focus on translational research.”

How is the tycoon contributing to ALS research?

Wang’s foundation has allocated over $200 million to ALS research since 2023, according to a press release from the China Association for Science and Technology. Key initiatives include funding CRISPR-based gene-editing trials at the Chinese Academy of Sciences and collaborations with the ALS Therapy Development Institute in the U.S.

“We are exploring multiple pathways, including stem cell therapy and AI-driven drug screening,” said a spokesperson for the Yifeng Foundation in a September 2024 statement. The organization also announced a partnership with the Mayo Clinic to establish a global ALS biobank, aiming to collect genetic data from 10,000 patients by 2025.

What are the risks and ethical concerns?

Experts caution that high-profile philanthropy in medical research can sometimes prioritize visibility over scientific rigor. Dr. Raj Patel, a bioethicist at Harvard University, noted, “When individuals with terminal illnesses drive research agendas, there’s a risk of overpromising results or diverting resources from more established projects.”

Wang’s public statements, including a 2024 interview with *South China Morning Post*, emphasize his personal stake in the work. “I’m not just funding this—it’s my life’s mission,” he said. However, his condition remains unverified by independent medical sources, as his treatment history has not been publicly disclosed.

What’s next for ALS research?

The global ALS research landscape is expanding, with over 200 clinical trials underway as of 2024, according to the ALS Global Research Database. Breakthroughs in gene therapy and biomarker identification are seen as critical next steps.

“If Wang’s efforts lead to a single viable treatment, it would be a major milestone,” said Dr. Maria Lopez, a neuroscientist at the University of Tokyo. “But the path from ambition to cure is long and fraught with uncertainty.”

As Wang’s story gains international attention, it underscores both the potential and the pitfalls of private-sector-driven medical research. For now, the focus remains on translating his commitment into measurable scientific progress.